Docetaxel plus Androgen Deprivation Therapy as First-Line Treatment in High Volume Metastatic Hormone-Sensitive Prostate Cancer

BACKGROUND: The addition of docetaxel to androgen deprivation therapy (ADT) as a first-line treatment has shown significant improvement in overall survival for patients with high volume metastatic hormone-sensitive prostate cancer (mHSPC). The CHAARTED and STAMPEDE trials have demonstrated the efficacy of combining docetaxel with ADT compared to ADT alone. METHODS: Between January 2012 and January 2014, 46 patients with newly diagnosed mHSPC and confirmed high-volume metastatic disease were enrolled. All patients received androgen deprivation therapy (a long-acting GnRH agonist, Goserelin acetate, and an androgen antagonist, Flutamide) alongside docetaxel administered intravenously at 75 mg/m² every three weeks for six cycles. RESULTS: The median follow-up period was 49 months with a standard error of 4.905 months. The median progression-free survival (PFS) was 28 months with a SE of 1.787, and the 2-year PFS rate was 58.6%. Median overall survival (OS) was 49 months with a SE of 4.905, with a 2-year OS rate of 85.9%. CONCLUSIONS: The combination of docetaxel and ADT should be considered the standard of care for men with newly diagnosed mHSPC.